| CAS NO: | 491577-61-8 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| Cas No. | 491577-61-8 |
| 别名 | (Z)-N-羟基-4-((5-(4-(5-异丙基-2-甲基噻唑-4-基)苯氧基)戊基)氧代)苯脒 |
| Canonical SMILES | N=C(C1=CC=C(OCCCCCOC2=CC=C(C3=C(C(C)C)SC(C)=N3)C=C2)C=C1)NO |
| 分子式 | C25H31N3O3S |
| 分子量 | 453.6 |
| 溶解度 | Soluble in DMSO |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | DW-1350 is a LTB4 receptor antagonist. DW-1350 is a LTB4 receptor antagonist. DW-1350 shows inhibitory effects against osteoclast in terms of differentiation, formation, fusion and bone absorption[1]. [1]. Kang JH, et al. 5-Lipoxygenase inhibitors suppress RANKL-induced osteoclast formation via NFATc1expression. Bioorg Med Chem. 2015 Nov 1;23(21):7069-78. |
m.cnreagent.com